Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Product name:

ATLANTISCAN

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02438380

Product Monograph/Veterinary Labelling:

Date: 2015-06-29 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

NOVA SCOTIA HEALTH AUTHORITY
1276 South Park Street, 1071b Centennial Building Cyclotron Facility
Halifax
Nova Scotia
Canada B3H 2Y9

Class:

Radiopharmaceutical

Dosage form(s):

Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

1

Schedule(s):

Schedule C

 

American Hospital Formulary Service (AHFS): See footnote 3

36:00.00  ,  78:00.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

V09IX04 FLUDEOXYGLUCOSE (18F)

Active ingredient group (AIG) number:See footnote5

0152591018

List of active ingredient(s)
Active ingredient(s) Strength
FLUDEOXYGLUCOSE 18F 200 MCI / ML
Version 4.0.2
Date modified: